Management Report Results of Operations, Financial Position, Assets and Liabilities Results of Operations 
RESULTS OF OPERATIONS
Sales
In 2007, we increased Group sales by 5 % to € 11,358 million (2006: € 10,777 million). Organic growth reached 6 % and acquisitions contributed 6 % to the growth in sales. Divestitures had an impact of -2 %. Currency translation had an effect of -5 %. The table shows the various influences on Fresenius’ Group sales. There were no significant consequences from the changes in product mix. Price effects in the dialysis care business contributed positively. In the foreseeable future no significant changes in these items are anticipated.
The largest regions in the Group were North America and Europe, which contributed 43 % each to total sales. These were followed by Asia-Pacific with 7 % and Latin America and Africa with 4 % and 3 %, respectively. Germany contributed 22 % to Group sales.
We increased sales significantly in all regions of the world. In North America, sales rose 10 % in constant currency. This was driven by organic growth of 5 % and the full-year consolidation of Renal Care Group. In Europe, organic growth of 5 % was the main driver. We again achieved strong organic growth in Asia-Pacific with 9 %, in Latin America with 10 %, and in Africa with 26 %.
Sales performance by business segment was as follows:
- Fresenius Medical Care achieved a sales increase of 5% to € 7,093 million in 2007 (2006: € 6,768 million). This was mainly driven by very good organic growth of 6%, as well as by acquisitions (7%). Currency translation had an effect of -7%. Divestitures had an impact of -1%. Fresenius Medical Care achieved strong growth both in dialysis care and in dialysis products.
- Fresenius Kabi increased sales by 7% to € 2,030 million
(2006: € 1,893 million). The company achieved strong
organic growth of 8%. Currency translation had an effect of -2%. This was mainly attributable to the weaker
currencies in South Africa, China, Mexico and Canada.
Performance in Asia-Pacific was excellent. Here,
Fresenius Kabi achieved strong organic growth of 22%.
